Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanzhi Gu

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Nature|March 20, 2025
Oncolytic virus VG161 in refractory hepatocellular carcinomaYinan Shen, Xueli Bai, Qi Zhang, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Nature|April 24, 2025
Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinomaYinan Shen, Xueli Bai, Qi Zhang, et al.
Journal of Cancer Research and Therapeutics|October 7, 2022
Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition)Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Journal of Cancer Research and Therapeutics|December 1, 2021
Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition)Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2021
[Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)]Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.
Journal of Cancer Research and Therapeutics|August 29, 2024
Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition)Baodong Liu, Xin Ye, Weijun Fan, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Nature|March 20, 2025
Oncolytic virus VG161 in refractory hepatocellular carcinomaYinan Shen, Xueli Bai, Qi Zhang, et al.
The Lancet. Oncology|June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 studyZhenggang Ren, Jianming Xu, Yuxian Bai, et al.
Nature|April 24, 2025
Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinomaYinan Shen, Xueli Bai, Qi Zhang, et al.
Journal of Cancer Research and Therapeutics|October 7, 2022
Clinical practice guidelines on image-guided thermal ablation of primary and metastatic lung tumors (2022 edition)Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Journal of Cancer Research and Therapeutics|December 1, 2021
Expert consensus on thermal ablation therapy of pulmonary subsolid nodules (2021 Edition)Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2021
[Expert Consensus for Thermal Ablation of Pulmonary Subsolid Nodules (2021 Edition)]Xin Ye, Weijun Fan, Zhongmin Wang, et al.
Signal Transduction and Targeted Therapy|August 6, 2025
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Yanqiao Zhang, Gang Wang, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.
Journal of Cancer Research and Therapeutics|August 29, 2024
Expert consensus on the multidisciplinary diagnosis and treatment of multiple ground glass nodule-like lung cancer (2024 Edition)Baodong Liu, Xin Ye, Weijun Fan, et al.
Pageof 8